{"filings":[{"id":94207,"accession_number":"0001493152-26-020939","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Biotricity exchanges common, options, warrants for Series C preferred with 40 votes per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14.14M common shares, 3.99M options, and 1.44M warrants exchanged for 1.96M Series C shares at a 10:1 ratio.","Series C carries 40 votes per share; converts into 59.6% of common upon a $15M+ qualified financing.","If no qualified financing by March 31, 2028, each Series C converts to 10 common shares.","Exchange holders include officers and directors; transaction is exempt under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106405,"accession_number":"0001493152-26-007369","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.","Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.","Third consecutive quarter of positive EBITDA and net operating income.","Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.","FDA clearance for AI clinical model expected in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.099,"consensus_revenue_estimate":null,"consensus_revenue_actual":11747607.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122760,"accession_number":"0001493152-25-024061","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.","Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.","Recurring TaaS technology fees $3.5M, 88.7% of total revenue.","Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.","CEO cites AI-driven automation and Biocore Pro adoption as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.057,"consensus_revenue_estimate":null,"consensus_revenue_actual":7759788.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175388,"accession_number":"0001493152-25-007938","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q3 FY25 revenue $3.6M (+21.7% YoY); net loss down 56.7% to $1.32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross margin improved to 76.4% from 72.9% YoY; recurring tech fees 94% of revenue at 81.4% gross profit.","Recurring Technology Fees rose 21.8% YoY to $3.39M; pure SaaS revenue up 22%.","SG&A reduced 20.5% to $2.38M from $3.0M; positive cash flow from operations second consecutive quarter, up 114.5% sequentially.","Net loss per share improved to $0.054 from $0.339 in Q3 FY24."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.498,"consensus_revenue_estimate":null,"consensus_revenue_actual":10087697.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192328,"accession_number":"0001493152-24-046908","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.","Net loss decreased 57% to $1.65M ($0.073/share) from $3.88M in Q2 FY24.","Recurring tech fees $3.06M (+12.2%), 94% of total revenue; flat fee portion up 34%.","Achieved positive cash flow on current operating basis in September; expects continued improvement.","SG&A cut 35.5% to $2.25M; total operating expenses down 34% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.469,"consensus_revenue_estimate":null,"consensus_revenue_actual":6468589.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208807,"accession_number":"0001493152-24-032861","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biotricity shareholders reject proposal to issue $6.6M in common stock upon Series B conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held August 15, 2024; all four director nominees elected.","Ratification of SRCO Professional Corporation as independent auditor approved with 12.24M votes for.","Proposal to issue up to $6.6M in common stock upon Series B Preferred conversion rejected (1.4M for, 10.9M against).","Elected directors: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, and Jainal Bhuiyan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208806,"accession_number":"0001493152-24-030615","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq delisting notice; trading suspended August 5, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist Biotricity's common stock; trading suspended at open Aug 5, 2024.","Non-compliance with minimum $35M market value of listed securities (MVLS) rule; compliance deadline extended to July 29, 2024.","Company expects stock to be quoted on OTC Pink under symbol BTCY; also applied to OTCQB.","Company has 15 days to request review of Panel's decision by Nasdaq Listing and Hearing Review Council."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208805,"accession_number":"0001493152-24-029939","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq bid price deficiency notice; 180-day cure period to Jan 22, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq Listing Rule 5550(a)(2) deficiency.","Company has until January 22, 2025 to regain compliance with minimum $1.00 closing bid for 10 consecutive days.","If non-compliant by Jan 22, may receive additional 180-day period to cure, subject to other listing standards.","Biotricity intends to monitor bid price and consider available options, including a reverse stock split.","No immediate impact on Nasdaq listing or trading of BTCY common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208804,"accession_number":"0001493152-24-028050","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Biotricity closes second tranche of Series B Preferred Stock private placement for $500,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing of 55 shares of Series B Convertible Preferred Stock at $9,090.91/share for gross proceeds of $500,000.","Combined with June 24 first closing (55 shares), total gross proceeds $1M from 110 shares.","Company must seek stockholder approval by August 15, 2024 for conversion-related matters.","Shares sold under Regulation D exemption; unregistered securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208803,"accession_number":"0001493152-24-027090","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biotricity shareholders approve non-public securities issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held July 12, 2024 approved issuance of securities in one or more non-public offerings.","11,152,302 votes for (98.2%), 195,450 against (1.7%), 10,626 abstain (0.1%).","Approval enables management to conduct private placements without further shareholder vote.","No specific offering amount, price, or timing disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226584,"accession_number":"0001493152-24-024888","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biotricity raises $500K in Series B Preferred placement; up to $1.5M additional","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 55 Series B Preferred shares at $9,090.91 each for gross proceeds of $500,000 on June 21, 2024.","Potential additional closings up to $1,500,000 through December 31, 2024 at investor's sole discretion.","Series B Preferred carries 8% cumulative dividend (15% on triggering event), convertible at $3.50/share.","Alternate conversion price at 80% (or 70% if suspended/delisted) of lowest VWAP during measuring period.","Company must seek stockholder approval by August 15, 2024; registration rights penalty of 100,000 common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226583,"accession_number":"0001493152-24-023126","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Biotricity issues 8.95M common shares on conversion of Series A Preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 8,952,172 common shares to investors upon conversion of 6,104 Series A Preferred shares plus accrued dividends and fees.","Shares were issued on June 4, 2024 under Section 4(a)(2) exemption; not registered with SEC.","The filing was made on June 7, 2024, reporting the unregistered sale of equity securities.","Conversion of preferred stock dilutes existing common shareholders by adding 8.95M shares to outstanding count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226582,"accession_number":"0001493152-24-021454","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Biotricity amends ATM offering to raise up to $2.68M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to March 2022 ATM agreement with H.C. Wainwright for up to $2,684,644 of common stock.","New registration statement on Form S-3 (File 333-279226) effective May 15, 2024, governs the offering.","Wainwright continues as sales agent; settlement cycle shortened to T+1 per updated rule.","Company adds representation that it is not an investment company under the 1940 Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226581,"accession_number":"0001493152-24-020909","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Biotricity raises $645,455 in third closing of Series B Preferred; total $2M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 71 shares of Series B Convertible Preferred to Ionic Ventures for $645,455 on May 15, 2024.","Combined with prior closings, total 220 Series B shares sold for $2M gross proceeds.","Filed amendment to Form S-3 to register 2,095,238 common shares issuable upon conversion.","Side letter waives 30-day limit on additional closings; company must deliver CA good-standing certificate within 10 days.","Stockholder approval required if conversions exceed Nasdaq rules; meeting to be held within 75 days of triggering event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226580,"accession_number":"0001493152-24-017744","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["3.01","3.02","8.01","9.01"],"status":"ready","headline":"Biotricity faces Nasdaq delisting for missing annual meeting; closes $354k private placement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biotricity on May 1, 2024 of non-compliance with annual meeting rule; additional delisting basis.","Company must respond to Nasdaq Hearings Panel by May 8, 2024; intends to hold meeting as soon as practicable.","On April 30, 2024, closed second tranche of private placement: 39 Series B Preferred shares for $354,545.","Registration Rights Agreement filed; failure to file or obtain effectiveness triggers 100,000 common shares per event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226579,"accession_number":"0001493152-24-015713","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Panel granted listing continuation after hearing on April 9, 2024.","Conditions include increasing outstanding shares via stock offerings and convertible conversions.","Company must receive shareholder approval for certain actions.","Biotricity must regain compliance with all Nasdaq listing requirements by July 29, 2024.","Previously received delisting notice for MVLS below $35M for 30 consecutive days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226578,"accession_number":"0001493152-24-012898","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Biotricity amends Series B Preferred Stock to remove voting rights; approved by holder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Certificate of Designations removes voting rights of Series B Preferred Stock (non-voting except as required by law).","Series B Preferred Stock: 600 shares designated at $10,000 stated value, cumulative 8% dividend (15% on Triggering Event).","Initial conversion price $3.50; alternate conversion at 80% of lowest VWAP (70% if delisted/reverse split).","Conversion capped at 4.99% beneficial ownership per holder and 19.9% of common stock absent shareholder approval.","Holder of outstanding Series B Preferred Stock approved amendment via written consent on April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245574,"accession_number":"0001493152-24-011344","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biotricity raises $1M in private placement of Series B Preferred Stock, with option for additional $1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1M from sale of 110 Series B Convertible Preferred shares at $9,090.91 each.","Company has 30-day option to require second closing for additional $1M (110 more shares).","Series B Preferred Stock: 8% cumulative dividend (15% upon triggering event), initial conversion price $3.50, alternate conversion at 80% of lowest VWAP.","Registration rights agreement requires filing registration statement within 45 days; failure triggers issuance of 100,000 common shares.","Voting agreement with certain stockholders to support Nasdaq-required stockholder approval for conversion shares issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245573,"accession_number":"0001493152-24-004806","cik":1630113,"company_name":"BIOTRICITY INC.","ticker":"BTCY","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biotricity receives Nasdaq delisting determination for failure to meet MVLS requirement; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.","Trading suspension on Nasdaq Capital Market set for Feb 8, 2024, unless the company appeals.","Company plans to request a hearing before the Nasdaq Hearings Panel to appeal and present a compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4118013.415384615,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}